PT3519569T - Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses - Google Patents
Vetores de vírus adenoassociados para o tratamento de mucopolissacaridosesInfo
- Publication number
- PT3519569T PT3519569T PT177775418T PT17777541T PT3519569T PT 3519569 T PT3519569 T PT 3519569T PT 177775418 T PT177775418 T PT 177775418T PT 17777541 T PT17777541 T PT 17777541T PT 3519569 T PT3519569 T PT 3519569T
- Authority
- PT
- Portugal
- Prior art keywords
- mucopolysaccharidoses
- treatment
- virus vectors
- adenoassociated virus
- adenoassociated
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 title 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382450 | 2016-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3519569T true PT3519569T (pt) | 2021-03-04 |
Family
ID=57123944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177775418T PT3519569T (pt) | 2016-09-30 | 2017-09-22 | Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11338046B2 (OSRAM) |
| EP (1) | EP3519569B1 (OSRAM) |
| JP (1) | JP7059285B2 (OSRAM) |
| CN (1) | CN109863243B (OSRAM) |
| AR (1) | AR109752A1 (OSRAM) |
| AU (1) | AU2017333336B2 (OSRAM) |
| ES (1) | ES2859661T3 (OSRAM) |
| PT (1) | PT3519569T (OSRAM) |
| TW (1) | TW201814044A (OSRAM) |
| WO (1) | WO2018060097A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2605798A1 (en) | 2010-07-12 | 2013-06-26 | Universidad Autònoma de Barcelona | Gene therapy composition for use in diabetes treatment |
| EP2692868A1 (en) | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| EP3622821A1 (en) * | 2013-05-15 | 2020-03-18 | Regents of the University of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| EP3194430A1 (en) | 2014-09-16 | 2017-07-26 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| WO2016087678A1 (en) | 2014-12-05 | 2016-06-09 | Universitat Autònoma De Barcelona | Viral vectors for the treatment of diabetes |
| EP3242945B1 (en) | 2015-01-07 | 2021-09-01 | Universitat Autònoma de Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| RU2020134965A (ru) | 2018-04-27 | 2022-04-27 | Спейскрафт Севен, Ллк | Генная терапия при дегенерации цнс |
| AU2019275969B2 (en) * | 2018-05-30 | 2025-07-10 | Esteve Pharmaceuticals, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type IV A |
| AU2019299970B2 (en) * | 2018-07-12 | 2025-12-11 | Spacecraft Seven, Llc | Gene therapy vectors for treatment of Danon disease |
| EP3914720B9 (en) | 2019-07-10 | 2023-09-27 | Masonic Medical Research Laboratory | Vgll4 with ucp-1 cis-regulatory element and method of use thereof |
| CN111718947B (zh) * | 2020-06-18 | 2022-08-23 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途 |
| IL300263A (en) | 2020-08-07 | 2023-03-01 | Spacecraft Seven Llc | Plakophilin-2 (PKP2) gene therapy using an AAV vector |
| CN114480454B (zh) * | 2020-10-27 | 2024-03-29 | 华东理工大学 | 用于治疗粘多糖贮积症ⅱ型的腺相关病毒载体、药物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232670B2 (en) * | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| DK2325302T3 (en) * | 2003-02-11 | 2016-03-14 | Shire Human Genetic Therapies | Cells expressing a sulfatase and a C-formylglycine-generating enzyme and methods and uses thereof |
| EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| AU2013216920B2 (en) | 2012-02-07 | 2016-09-22 | Global Bio Therapeutics, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| CN105916990B (zh) * | 2013-08-02 | 2020-02-04 | 巴塞罗那自治大学 | 用于转导脂肪组织的腺相关病毒载体 |
| CN105745326A (zh) * | 2013-10-24 | 2016-07-06 | 优尼科Ip有限公司 | 用于基因治疗神经疾病的aav-5假型载体 |
| GB201322798D0 (en) * | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| AR100419A1 (es) | 2014-05-14 | 2016-10-05 | Esteve Labor Dr | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico |
| SG11201706445SA (en) | 2015-02-10 | 2017-09-28 | Genzyme Corp | Enhanced delivery of viral particles to the striatum and cortex |
| US9981021B1 (en) * | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
-
2017
- 2017-09-22 CN CN201780060410.7A patent/CN109863243B/zh active Active
- 2017-09-22 EP EP17777541.8A patent/EP3519569B1/en active Active
- 2017-09-22 JP JP2019538714A patent/JP7059285B2/ja active Active
- 2017-09-22 PT PT177775418T patent/PT3519569T/pt unknown
- 2017-09-22 AU AU2017333336A patent/AU2017333336B2/en active Active
- 2017-09-22 WO PCT/EP2017/074081 patent/WO2018060097A1/en not_active Ceased
- 2017-09-22 ES ES17777541T patent/ES2859661T3/es active Active
- 2017-09-22 US US16/337,953 patent/US11338046B2/en active Active
- 2017-09-29 AR ARP170102704A patent/AR109752A1/es unknown
- 2017-09-30 TW TW106133935A patent/TW201814044A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017333336B2 (en) | 2023-11-09 |
| US11338046B2 (en) | 2022-05-24 |
| EP3519569B1 (en) | 2020-12-02 |
| AR109752A1 (es) | 2019-01-23 |
| AU2017333336A1 (en) | 2019-04-11 |
| ES2859661T3 (es) | 2021-10-04 |
| EP3519569A1 (en) | 2019-08-07 |
| JP2019528793A (ja) | 2019-10-17 |
| US20190231900A1 (en) | 2019-08-01 |
| CN109863243B (zh) | 2023-07-28 |
| JP7059285B2 (ja) | 2022-04-25 |
| TW201814044A (zh) | 2018-04-16 |
| CN109863243A (zh) | 2019-06-07 |
| WO2018060097A1 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201708039B (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
| PT3519569T (pt) | Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| ZA201901430B (en) | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection | |
| IL248538A0 (en) | Vector viruses unrelated to the treatment of lysosomal storage disorders | |
| IL258002A (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL250960A0 (en) | Combined treatment of sinecriviroc for the treatment of leprosy | |
| ZA201900156B (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| IL256327B (en) | Pharmaceutical preparations for the treatment of viral problems of the eye | |
| IL264950A (en) | Combined treatments for the treatment of malignant liver cell carcinoma | |
| IL279054A (en) | Adeno-associated virus vectors for the treatment of mucopolysacridoses type IV A | |
| IL258137B1 (en) | HIV treatment measures | |
| IL253617A0 (en) | Snekribirock for the treatment of leprosy | |
| SI3471732T1 (sl) | Liposomi za zdravljenje virusnih infekcij | |
| HUE049682T2 (hu) | Új eljárások vemurafenib elõállítására | |
| HK40006685A (en) | Dihydropyranopyrimidines for the treatment of viral infections |